Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report

Seeking AlphaJun 30 03:44

Cassava Sciences Shares Plunge on Indictment Against Former Advisor -- Barrons.com

By Anita Hamilton A federal indictment of a lead scientist working as an advisor for Cassava Sciences, which has an Alzheimer's drug in late-stage clinical trials, sent shares sharply down Friday. T

Barron'sJun 29 06:33

Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294

Needham analyst Ami Fadia maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $294.According to TipRanks data, the analyst has a success rate of 43.9% and a total average

Futu NewsJun 28 18:33 · Ratings

Express News | WCH China: Will launch a medical insurance plan for the new Alzheimer's disease drug, Luncalock monoclonal antibody.

BreakingsJun 28 17:48

Needham Reiterates Buy on Biogen, Maintains $294 Price Target

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

BenzingaJun 28 17:33

Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease

Biogen (BIIB) said Thursday it has launched the humanized anti-soluble aggregated amyloid-beta monoclonal antibody Leqembi in China with Eisai Co. Ltd. Leqembi received approval in January as a treatm

MT NewswiresJun 28 16:24